The Brand Name ERLONAT Has Generic Salt :: ERLOTINIB 

ERLONAT  Is From Company Natco Priced :: Rs. 2000

ERLONAT have ERLOTINIB is comes under Sub class Anti Neoplastic Agents of  Main Class Anti Neoplastic Agents

Main Medicine Class:: Anti Neoplastic Agents  Sub Medicine Class :: Anti Neoplastic Agents 

Indications for Drugs ::

Small cell lung cancer, Pancreatic cancer

Drug Dose ::

Adult: PO Locally advanced or metastatic non small cell lung carcinoma 150 mg once daily. Locally advanced, unresectable or metastatic pancreatic cancer W/ gemcitabine: 100 mg/day. Dose modifications may be required when used with strong CYP3A4 inhibitors/inducers; or in cigarette smoking patients.

Contraindication ::

Hypersensitivity.

Drug Precautions ::

Pregnancy and lactation. Interrupt Erlotinib therapy if patient develops unexplained pulmonary symptoms e.g. dyspnoea, cough, fever; discontinue therapy if interstitial lung disease is diagnosed. Monitor liver functions periodically; extreme caution is needed if total bilirubin is 3x >ULN; close monitoring is required in patients with hepatic impairment. Interrupt/discontinue therapy if severe changes in liver functions (doubling of total bilirubin and/or tripling of transaminases) occur. Interrupt therapy in the event of dehydration especially in patients with predisposing factors to renal failure. Monitor renal function and serum electrolytes in patients at risk of dehydration. Interrupt or discontinue therapy if patient develops severe bullous and exfoliative skin disorders; eye pain or other acute/worsening ocular disorders. If patient develops GI perforation, discontinue therapy permanently. Patients with CV disorders. Monitor prothrombin time/INR in patients taking warfarin or other coumarin-derivative anticoagulants.

Drug Side Effects ::

Adverse reactions reported with monotherapy: Fatigue, diarrhoea, anorexia, nausea, abdominal pain, stomatitis, weight loss, rash, pruritus, acne, dermatitis acneiform, dry skin, cough, dyspnoea, infection, conjunctivitis, conjunctivitis sicca, liver function test abnormalities. Adverse reactions reported when used with gemcitabine: Fatigue, rash, nausea, anorexia, diarrhoea, abdominal pain, vomiting, weight decreased, infection, oedema, pyrexia, constipation, bone pain, dyspnoea, stomatitis, myalgia, depression, dyspepsia, cough, dizziness, headache, insomnia, alopecia, anxiety, neuropathy, flatulence, rigors.

Pregnancy category ::

4

Drug Mode of Action ::  

Erlotinib is an epidermal growth factor receptor/human epidermal growth factor receptor type 1 (EGFR/HER1) tyrosine kinase inhibitor. It reversibly inhibits the kinase activity of EGFR, preventing autophosphorylation of tyrosine residues associated w/ the receptor, thereby inhibiting further downstream signaling and resulting in cell death.

Drug Interactions ::

Increased serum levels w/ potent CYP3A4 inhibitors (e.g. ketoconazole, clarithromycin, atazanavir). CYP3A4 inducers (e.g. rifampicin, carbamazepine, phenytoin, phenobarbital) may reduce exposure of erlotinib. Increased serum levels w/ potent inhibitors of CYP1A2 (e.g. ciprofloxacin) or capecitabine. Use w/ P-glycoprotein inhibitors (e.g. ciclosporin, verapamil) may cause altered distribution or elimination of erlotinib. Drugs that increase the pH of the GI tract (e.g. antacids, H2-receptor antagonists, or PPIs) may reduce the solubility of erlotinib thus lowering its bioavailability. Concomitant use w/ warfarin or other coumarin derivates may increase INR and bleeding events.